SCHEMBL7219583

SCHEMBL7219583

CCCCS(=O)(=O)Nc1ccc(Oc2cccc3c(C(=O)O)cccc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.51
MRGPRX1 Q96LB2 3/20 0.47
MCL1 Q07820 2/20 0.47
BCL2L1 Q07817 1/20 0.47
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 1/20 0.47
MITF O75030 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
CRHBP P24387 1/20 0.41
FNTA P49354 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7221201 0.90 AR (0.47) ARMRGPRX1MCL1BCL2L1POLB
SCHEMBL8307237 0.83 AR (0.56) ARMRGPRX1MCL1BCL2L1POLB
SCHEMBL3555020 0.79 AR (0.61) ARLMNAMEN1KMT2AL3MBTL1
SCHEMBL7220116 0.79 BCL2L1 (0.48) ARMCL1BCL2L1POLBLMNA
SCHEMBL7219476 0.77 MRGPRX1 (0.52) MRGPRX1MCL1BCL2L1
SCHEMBL9446997 0.74 AR (0.49) ARMRGPRX1POLBLMNAALDH1A1
SCHEMBL7220505 0.74 AR (0.50) ARMRGPRX1POLBLMNAALDH1A1
SCHEMBL9447116 0.72 AR (0.52) ARMRGPRX1LMNAALDH1A1GAA
SCHEMBL7226423 0.72 MRGPRX1 (0.45) ARMRGPRX1MCL1BCL2L1MEN1
SCHEMBL8231736 0.71 THRA (0.59) ARLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6573278-B2 For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma BAYER AKTIENGESELLSCHAFT (DE) 2003-06-03 US disclosed
US-20020072529-A1 Arylsulfonamides and analogues BAYER INTELLECTUAL PROPERTY GMBH (DE) 2002-06-13 US disclosed
US-6262112-B1 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE BAYER AKTIENGESELLSCHAFT (DE) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072529-A1 Arylsulfonamides and analogues ARSA, PRSS12, SNCA AR 3114/4885MRGPRX1 1609/4885MCL1 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.